Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total Liver Disease Franchise Product Sales by Year
Total Liver Disease Franchise Product Sales — Worldwide YoY growth (%) (%)
Gilead Sciences Total Liver Disease Franchise Product Sales: 6.0% in FY2025, down 3.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Liver Disease | 844 | 719 | 17% | 3,217 | 3,021 | 6%”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Reported in Form 8-K Total Revenue Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Liver Disease Franchise Product Sales — Worldwide YoY growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.0% | -3.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 9.0% | +10.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2023 | Dec 31, 2023 | -1.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total Liver Disease Franchise Product Sales (%), annual FY2023–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-total-yoy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.